A team led by researchers at Mount Sinai has identified in mice a potential therapeutic target for dry eye disease.
The researchers found markers for stem cell populations that maintain distinct regions of the meibomian glands - tiny oil glands along the edges of the eyelids - and uncovered the hedgehog (Hh) cell-cell signaling pathway, which is broadly important in development and disease, as a key regulator of meibomian gland stem cell proliferation and tissue regeneration. They found that increased Hh signaling is a hallmark of human meibomian gland carcinoma, a rare and aggressive cancer of the eyelid. Furthermore, the team discovered that aged glands show decreased Hh signaling and decreased epidermal growth factor receptor (EGFR) signaling, as well as impaired innervation and a loss of collagen in niche fibroblasts, suggesting that changes in both glandular epithelial cells and their surrounding microenvironment contribute to age-related degeneration.
These discoveries suggest that targeting Hh and EGFR signaling to stimulate stem cell activity in the meibomian glands could be a potential therapeutic option to treat evaporative dry eye disease.
Meibomian glands secrete lipid-rich meibum to prevent tear evaporation and protect the eye surface. Aging-related shrinkage of the meibomian glands may result, in part, from stem cell exhaustion and is associated with evaporative dry eye disease, a common condition that causes swollen eyelids, itchy eyes, or blurred vision. Symptoms may be lessened with warm compressions, artificial tears, and thermal pulsation, but these treatments are only partially effective.
“Despite the prevalence of dry eye disease, the stem cells and molecular mechanisms that control homeostasis of the meibomian gland, and are impaired in aging, are poorly understood,” said senior author Sarah E. Millar, Ph.D., dean for basic science of the Icahn School of Medicine at Mount Sinai, the Lillian and Henry M. Stratton Professor of Gene and Cell Medicine, director of the Institute for Regenerative Medicine, and director of the Black Family Stem Cell Institute. “We hope that our work will eventually result in new, more effective therapies for this very common condition.”